Literature DB >> 21945710

Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats.

Adriana K Burlá1, Núbia S Lobato, Zuleica B Fortes, Wille Oigman, Mario Fritsch Neves.   

Abstract

BACKGROUND: Human obesity has been associated with alterations of vascular structure, especially in large and medium arteries, but the effects of insulin-sensitizers are not well known.
METHODS: Twenty-five male Wistar rats received subcutaneous injections of monosodium glutamate (MSG) or an equivalent volume of vehicle from the second to the sixth day after birth, At 16 weeks of age, five MSG rats started receiving an oral treatment with metformin (300 mg/kg) which was maintained for six weeks, composing five groups: control 16 weeks (CON-16), MSG 16 weeks (MSG-16), control 22 weeks (CON-22), MSG 22 weeks (MSG-22), and MSG plus metformin 22 weeks (MET-22). Systolic blood pressure (BP) was verified weekly. The lumen diameter and media thickness, media cross-sectional area (CSA) and growth index of the intramyocardial arterioles were measured. Cardiac interstitial and perivascular collagen density were also evaluated.
RESULTS: Systolic BP was significantly increased in the MSG-22 comparing to MSG-16 group. Insulin resistance was confirmed by HOMA-IR index and metformin-treated group presented reduction of insulin levels at week 22. The morphology analysis showed greater media-to-lumen ratio and CSA in the obese groups, which were reduced by the metformin treatment. Connective tissue deposition in the perivascular region of the left ventricle was significantly higher in the obese groups which was attenuated by metformin.
CONCLUSIONS: Hypertrophic vascular remodeling and cardiac collagen deposition were significantly evident in MSG-induced obese rats. Metformin treatment was able to reduce insulin resistance and attenuated this adverse cardiac and vascular remodeling.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945710     DOI: 10.1016/j.ijcard.2011.09.012

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning.

Authors:  S E Meshkani; D Mahdian; K Abbaszadeh-Goudarzi; M Abroudi; G Dadashizadeh; J-D Lalau; M E De Broe; H Hosseinzadeh
Journal:  J Endocrinol Invest       Date:  2019-05-16       Impact factor: 4.256

2.  Metformin Is Associated With a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study.

Authors:  Anna Ostropolets; Pierre A Elias; Michael V Reyes; Elain Y Wan; Utpal B Pajvani; George Hripcsak; John P Morrow
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-02-07

3.  Obesity is associated with lower coronary microvascular density.

Authors:  Duncan J Campbell; Jithendra B Somaratne; David L Prior; Michael Yii; James F Kenny; Andrew E Newcomb; Darren J Kelly; Mary Jane Black
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

4.  Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes.

Authors:  Ricardo Fontes-Carvalho; Ricardo Ladeiras-Lopes; Paulo Bettencourt; Adelino Leite-Moreira; Ana Azevedo
Journal:  Cardiovasc Diabetol       Date:  2015-01-13       Impact factor: 9.951

5.  Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism.

Authors:  Fei Luo; Yuan Guo; Guiyun Ruan; Xiangping Li
Journal:  Lipids Health Dis       Date:  2016-06-21       Impact factor: 3.876

Review 6.  Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid.

Authors:  Gianfranco Baronzio; Gurdev Parmar; Miriam Baronzio
Journal:  Front Oncol       Date:  2015-07-23       Impact factor: 6.244

7.  Oral Metformin Treatment Counteracts Adipoinsular Axis Dysfunction in Hypothalamic Obese Rats.

Authors:  Daniel Castrogiovanni; Luisina Ongaro; Guillermina Zuburía; Andrés Giovambattista; Eduardo Spinedi
Journal:  Int Sch Res Notices       Date:  2015-04-05

8.  Pentamethylquercetin Attenuates Cardiac Remodeling via Activation of the Sestrins/Keap1/Nrf2 Pathway in MSG-Induced Obese Mice.

Authors:  Jingxia Du; Wei He; Cai Zhang; Jianzhao Wu; Zhi Li; Min Wang; Shuying Feng; Gaofeng Liang
Journal:  Biomed Res Int       Date:  2020-01-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.